SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trillium Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (84)8/31/2017 12:15:49 PM
From: tuck  Respond to of 294
 
So, TRIL will continue to develop the EGFR inhibitor, while putting up the BET inhibitor for immediate sale. Clearly, they've shelved the proteasome inhibitor entirely.
I dug around looking for publications and IP related to the Fluorinov compounds. As far as the latter goes, it is worryingly sparse. The only IP is for fluorinated epoxyketones as proteasome inhibitors. Given the latter, maybe it's good the former is also sparse.

Gefitinib targets egfr and has fluorine in it . . .

Cheers, Tuck



To: tuck who wrote (84)11/27/2017 12:24:10 PM
From: Bladerunner17  Respond to of 294
 
My personal hematologist thinks that TTI-2341 is the real gem of the pipeline. He's invested.

Bladerunner


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News